- Ranked fifth on the list of the best Russian pharmaceutical companies, Forbes
- One of the top 3 fast-growing Russian technology companies, the TechUp rating
- One of the top 10 leading manufacturers by hospital procurement volume, AlphaRM
- It is included in the list of Russian systemically important companies by the Ministry of Industry and Trade of Russia
![](https://landing.gxpnews.net/wp-content/uploads/2020/07/new-map-pharmasyntez-eng.png)
![pharmasintez-671 pharmasintez-671](https://landing.gxpnews.net/wp-content/uploads/elementor/thumbs/pharmasintez-671-p697xae6oc8z9nja24jamu8nen5y8jueg948anuxfw.jpeg)
-
JSC Pharmasyntez, Irkutsk:
Antituberculosis, antitumor, antiretroviral agents, injection solutions, and hospital antibiotics. -
LLC BratskChemSyntez, Bratsk:
Active pharmaceutical ingredients of different pharmacologic classes. -
LLC EAST-PHARM, Ussuriysk:
Solutions for infusion. -
LLC Pharmasyntez-Tyumen, Tyumen:
Solutions for infusion, antidiabetic agents in solid dosage forms, hormonal drugs, and radiopaque contrast media. -
JSC Pharmasyntez-Nord, Saint Petersburg:
Antitumor agents, drug products included in the 12 High-Cost Nosologies List, Sputnik Light vaccine.
- More than 200 products of various dosage forms and pharmaceutical classes are currently manufactured at Pharmasyntez Group plants.
- The Pharmasyntez Group’s annual capacity is more than 76 mln packs.
- Export Geography: 30 pharmaceutical products of various pharmaceutical classes are exported to 10 countries (Azerbaijan, Kazakhstan, Uzbekistan, Kyrgyzstan, Belarus, Turkmenistan, Mongolia, Guinea, Romania, North Korea).
![](https://landing.gxpnews.net/wp-content/uploads/2020/07/farmasintez-lek1.jpeg)
Investments
The Company is one of the largest Russian pharmaceutical industry investors. The cumulative volume of investments in projects to be completed by 2024 is over 23 bln rubles.
Pharmasyntez-Nord, Saint Petersburg
2021: Facility for research and production of biological drugs for the treatment of cancer, autoimmune diseases, and endocrine diseases.
2021: Department for the production of Gam-COVID-Vac (Sputnik Light) vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
Pharmasyntez-Tyumen, Tyumen
2021: Plant for hormonal drug production.
2024: Plant for production of heart disease drugs.
East-Pharm, Ussuriysk
2023: Plant for parenteral nutrition production in the Kaluga Special Economic Zone.
BratskChemSyntez, Bratsk
2023: Building for general APIs large scale production with an output of 1000 tons per year.
The company employs
highly skilled professionals
Innovation
![](https://landing.gxpnews.net/wp-content/uploads/2020/07/pharmasyntez-2-1280-1068x7121-1.jpeg)
There are two innovation drugs:
- Perchlozone® (INN Thioureidoiminomethylpyridinium perchlorate) for the treatment of pulmonary tuberculosis and MDR-TB. Pharmasyntez is a developer and sole manufacturer of this agent.
- Saterex® (INN Gosogliptin) for the treatment of type 2 diabetes mellitus. A full cycle production of the drug including pharmaceutical ingredient synthesis is carried out by the Company.
Drug candidate:
- Seroguard® (INN Adezmapimod) for the prevention and reduction of adhesion formation following a surgery. Phase III clinical trials are ongoing in Russia and in foreign countries.
License Agreements
- 2019 — acquisition of rights to scientific research results for the creation of a drug for the treatment and prophylaxis of tick-borne encephalitis.
- Encemab®, the Institute of Chemical Biology and Fundamental Medicine, SB RAS, Russia.
- 2020 — license agreement for the production of a drug for the treatment of orphan diseases.
- ISU305 (INN Eculizumab), ISU Abxis, South Korea.
- 2021 — commercialization of an innovative drug for leukemia.
- PF-114, Fusion Pharma, Russia, a resident of the biomedical technologies cluster of the Skolkovo Foundation.
Pharmasyntez against COVID -19
Production of large-scale batches of the drugs for the treatment of the new coronavirus infection:
- Remdeform (INN Remdesivir)
- Favibirin (INN Favipiravir)
A full cycle production including the production of Remdesivir and Favipiravir APIs is carried out at the BratskChemSyntez plant in Bratsk, Irkutsk Region, Russia.
* Included in the treatment regimen for the new coronavirus infection by the Ministry of Healthcare of the Russian Federation
Contacts
![](https://landing.gxpnews.net/wp-content/uploads/2021/04/pharmasyntez_en-900x263-1-1-1.png)
Irkutsk Office:
184, Rosa Luxemburg St., Irkutsk, Russia, 664040
Tel.: +7 3952 550355
Moscow Office:
12, Presnenskaya naberezhnaya, Federation Tower (West), 42th floor, Moscow, Russia, 123100
Tel.: +7 495 7505437